Table 3.
The immunohistochemistry results of β-catenin protein evaluation in patients with different types of bone cancer.
| Groups | Expression patterna | P value | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Total number | Absence of immunoreactivity (negative) | Weak intensity | Medium intensity | Strong intensity | ||||||
| N | % | N | % | N | % | N | % | |||
| Malignant tumors | 78 | 13 | 16.69% | 21 | 26.92% | 25 | 32.05% | 19 | 24.35% | < 0.0001 |
| Benign tumors | 72 | 35 | 48.61% | 32 | 44.44% | 5 | 6.9% | 0 | 0 | |
| Chemotherapy-received | 32 | 1 | 3.125% | 4 | 12.5% | 15 | 46.87% | 12 | 37.5% | < 0.0001 |
| Chemotherapy-not received | 46 | 14 | 30.43% | 17 | 36.95% | 11 | 23.91% | 4 | 8.69% | |
| Metastatic tumors | 29 | 1 | 3.44% | 0 | 0 | 11 | 37.93% | 17 | 58.62% | < 0.0001 |
| Non-metastatic tumors | 49 | 12 | 24.48% | 21 | 42.85% | 14 | 28.57% | 2 | 4.08% | |
| Recurrent tumors | 15 | 0 | 0 | 0 | 0 | 4 | 26.66% | 11 | 73.33% | < 0.0001 |
| Non-recurrent tumors | 34 | 9 | 26.47% | 13 | 38.23% | 11 | 32.45% | 2 | 5.88% | |
| High grade tumors | 44 | 1 | 2.27% | 4 | 9.09% | 20 | 45.45% | 19 | 43.18% | < 0.0001 |
| Low grade tumors | 22 | 7 | 31.81% | 10 | 45.45% | 5 | 22.72% | 0 | 0 | |
| Osteosarcoma | 26 | 3 | 11.53% | 5 | 19.23% | 8 | 30.76% | 10 | 38.46% | 0.433 |
| Ewing's sarcoma | 26 | 6 | 23.07% | 8 | 30.76% | 9 | 34.61% | 3 | 11.53% | |
| Chondrosarcoma | 26 | 4 | 15.38% | 8 | 30.76% | 8 | 30.76% | 6 | 23.07% | |
| Osteochondroma | 24 | 12 | 50% | 11 | 45.83% | 1 | 4.16% | 0 | 0 | 0.871 |
| Giant cell tumor | 24 | 13 | 54.16% | 9 | 37.5% | 2 | 8.33% | 0 | 0 | |
| Exostosis | 24 | 10 | 41.66% | 12 | 50% | 2 | 8.33% | 0 | 0 | |
aThe expression pattern was determined based on the staining intensity of β-catenin antibody that is described in “Material and methods”.